CV Sciences (CVSI) EBITDA Margin (2013 - 2026)
CV Sciences (CVSI) posted EBITDA Margin of 9.95% for Q1 2026, down 338.86% sequentially from 2.27% in Q4 2025, and down 1026.0% YoY from 1.07% in Q1 2025.
CV Sciences (CVSI) EBITDA Margin (2013 - 2026) Analysis & Trends
CV Sciences has reported EBITDA Margin for 14 years, with the latest figure at 9.95% in Q1 2026.
- Quarterly EBITDA Margin fell 1026.0% year-over-year to 9.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.97% (up 421.0% YoY) and the FY2025 annual result came in at 3.41%, up 1054.0% from the prior year.
- EBITDA Margin retreated to 9.95% in Q1 2026 per CVSI's latest filing, from 2.27% in the prior quarter.
- Over five years, EBITDA Margin peaked at 138.91% in Q1 2023 and troughed at 55.94% in Q2 2022.
- A 5-year average of 10.04% and a median of 14.74% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin surged 17298 bps in 2023, then slumped 15440 bps in 2024.
- Over 5 years, EBITDA Margin stood at 54.92% in 2022, then soared by 57 bps to 23.39% in 2023, then climbed by 29 bps to 16.63% in 2024, then jumped by 86 bps to 2.27% in 2025, then slumped by 339 bps to 9.95% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 9.95%, 2.27%, and 8.45% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -10.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.08% |
| Mar 31, 2026 | -9.95% |
| Dec 31, 2025 | -2.27% |
| Sep 30, 2025 | -8.45% |
| Jun 30, 2025 | -3.62% |
| Mar 31, 2025 | 0.31% |
| Dec 31, 2024 | -16.63% |
| Sep 30, 2024 | -8.82% |
| Jun 30, 2024 | -14.74% |
| Mar 31, 2024 | -15.49% |
| Dec 31, 2023 | -23.39% |
| Sep 30, 2023 | -10.69% |
| Jun 30, 2023 | -27.13% |
| Mar 31, 2023 | 138.91% |
| Dec 31, 2022 | -54.92% |
| Sep 30, 2022 | -23.78% |
| Jun 30, 2022 | -55.94% |
| Mar 31, 2022 | -34.07% |
| Dec 31, 2021 | -177.96% |
| Sep 30, 2021 | -58.35% |